Cite
MLA Citation
Raburn M Mallory et al.. “Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial.” Lancet infectious diseases, vol. 22, no. 11, 2022, pp. 1565–1576. http://access.bl.uk/ark:/81055/vdc_100168599634.0x000012